A phase 2 study sought to determine the benefits of high-intensity interval training on cardiovascular health and biochemical disease progression in men with prostate cancer under active surveillance.
Patients with BRCA1/2 alterations had the best response to talazoparib.
Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.
Early results demonstrate the potential of personalized 3D-printed shields for protecting healthy GI tissue in patients undergoing radiotherapy for prostate cancer.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.